A Prospective, Multicenter, Open-label, Single-arm, Phase 2 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Selexipag in Children With Pulmonary Arterial Hypertension

Trial Profile

A Prospective, Multicenter, Open-label, Single-arm, Phase 2 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Selexipag in Children With Pulmonary Arterial Hypertension

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs Selexipag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 11 Jul 2018 Planned initiation date changed from 30 Jun 2018 to 30 Jul 2018.
    • 16 May 2018 Planned End Date changed from 23 Nov 2025 to 30 Dec 2025.
    • 16 May 2018 Planned primary completion date changed from 2 Aug 2018 to 30 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top